Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated significant metabolic benefits for patients with type 2 diabetes mellitus (T2DM) and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.